Remarkably, most of the genes from the E2-response signature that were downregulated after Dex treatment were identified as markers of bad prognosis in ER+ breast cancer (KMplotter (Győrffy, 2021)), specifically in patients who had undergone various therapies (Appendix Fig. S3e), suggesting that GR activation might be beneficial in advanced ER+ breast cancer. This evidence concerns the gene NR3C1 and breast carcinoma.